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Editorial
Research Amidst the Pandemic
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Cancer patients need access to promising investigational therapies, available only through
clinical trials, and the emergence of COVID-19 and the resulting pandemic became an
emerging threat to fulfilling that need. Many academic medical centers were pausing their
clinical research programs, diverting their resources and sheltering their teams. Sarah Cannon, the Cancer Institute of HCA Healthcare, made the decision to stay safe, but stay the
course.
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Cancer patients need access to promising
investigational therapies, available only through
clinical trials, and the emergence of COVID-19
and the resulting pandemic became an emerging threat to fulfilling that need. Many academic medical centers were pausing their clinical
research programs, diverting their resources
and sheltering their teams. Sarah Cannon, the
Cancer Institute of HCA Healthcare, made the
decision to stay safe, but stay the course. We
knew providing these therapies, often personalized to their tumor’s molecular profile, was
essential to cancer patients.
In fact, during the months of April and May
2020, Sarah Cannon’s trial enrollments actually
increased as other cancer centers closed and
patients were referred to our programs from
all over the country. Pharma and biotech were
informed of the precautions undertaken, and
were largely supportive and appreciative as we
kept our patients and colleagues safe. Some of
the steps taken included partnering with our
sites to provide telehealth appointments and
reduce in-person visits, working with sponsors
and regulators to allow patients to obtain labs
and scans closer to where they live. The infrastructure and the power of Sarah Cannon’s
community-based network was on display for
cancer researchers everywhere.
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Investments in information technology and
digital platforms paid off handsomely during
the crisis. Examples of the successes included
e-consent, enabling informed consent between
research nurses and patients who were in the
safety of their homes, as well as remote monitoring and data capture for sponsors and contract research organizations (CROs), allowing
studies to proceed safely and on time. These
advanced processes and safety precautions
resulted in Sarah Cannon initiating over 40
first-in-human cancer trials and a total of 200+
cancer clinical trials during 2020. These studies
included several one-of-a-kind targeted agents
for rare mutations, novel cellular and immunotherapy approaches, and personalized cancer
vaccines, as well as continuing the groundbreaking work on the CRISPR gene editing
technology for sickle cell anemia.1
HCA Healthcare Research Institute (HRI) is
a recently formed entity designed to expand
research opportunities across our markets in a
variety of diseases and specialties while utilizing the operational infrastructure of the Sarah
Cannon Research Institute. With the emergence of COVID-19, HRI was the appropriate
center to coordinate, implement, and support
the various clinical trials needed to study this
lethal virus. Under the executive leadership of
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Dr. Jon Perlin, HCA Healthcare’s chief medical
officer and president of COG, and co-chaired
by Dr. Ken Sands, an epidemiologist and HCA
Healthcare’s chief safety officer, along with myself, a COVID-19 research steering committee
and task force was put in place, with members
representing various service lines, facilities and
clinical specialties.
HRI’s efforts were quickly directed toward
epidemiologic and registry research to better understand the disease and its impact on
our diverse patient populations. Genospace,
the bioinformatics and computational biology division of Sarah Cannon, based in Boston,
was instrumental in this effort as data on over
100,000 COVID positive patients were captured across the system, including more than
60,000 who were hospitalized. Insights into
age, race and ethnicity, along with comorbid
conditions such as diabetes, obesity and lung
disease were able to be quickly analyzed and
explored. The impact and risks of drugs such as
hydroxychloroquine, famotidine and dexamethasone were assessed in this vast database.
Numerous manuscripts have been prepared
and submitted, describing our findings for the
broader public and scientific community.
Participation in therapeutic, preventive and
testing strategies were also able to be implemented across the HCA Healthcare network.
With the support of HRI and Sarah Cannon,
our colleagues opened the convalescent plasma
study at 175 HCA Healthcare facilities within
just a few weeks, enrolling over 10,000 patients
and helping the world understand when and
how this therapy should be utilized. Other
treatment modalities studied include antivirals, anti-inflammatories and antibodies, plus
strategies such as extracorporeal membrane
oxygenation (ECMO) and prone ventilation.
We have also participated in numerous testing
modalities, including rapid antigen, classic PCR
and antibody tests, for both our patients and
our health care workers and colleagues.
On the prevention front, similar strategies
have been deployed to participate in the clinical
trials of vaccine approaches, partnering with
pharma, biotechs, and CROs to provide access to our HCA Healthcare communities. As I
write this column, preliminary, but promising
results from two of the vaccine trials have been
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released. Of note, both biotechs, Moderna and
BioNTech (with Pfizer), had worked with Sarah
Cannon on clinical trials of their personalized
cancer vaccines, utilizing the same technology being deployed to prevent COVID-19. In
fact, a Sarah Cannon patient was featured in a
news release two years ago when she took the
first ever cancer vaccine designed to fight her
specific, individual cancer, and for which she is
doing well. Vaccines are the great hope for our
society getting past this pandemic, and we are
still actively opening new vaccine studies at
various locations in our markets.
Within HCA Healthcare, Sarah Cannon and HRI,
we can be proud that during this pandemic, research not only did not slow down or stop, but
it in fact expanded and accelerated. The contributions made and the ongoing observations
will help greatly in the fight against COVID-19
and in our continued battle against cancer.
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